Novartis AG (FRA:NOT) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 24, 2026)


FRA:NOT Novartis AG FRA:NOT
83 GF Score
Price €131.52
GF Value €109.77
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Novartis AG Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Novartis AG's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:NOT vs LLY, JNJ, ABBV: Margin of Safety % (DCF Earnings Based) Comparison

For the Drug Manufacturers - General subindustry, Novartis AG's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Novartis AG Margin of Safety % (DCF Earnings Based) vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Novartis AG's Margin of Safety % (DCF Earnings Based) falls into.


FRA:NOT
83GF Score
Novartis AG FRA:NOT
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novartis AG (FRA:NOT) Overvalued in 2026?

Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued. The current stock price of €131.52 is trading 19.8% above its estimated GF Value™ of €109.77. GuruFocus considers Novartis AG to be Modestly Overvalued.

Key valuation signals for FRA:NOT:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €109.77 vs. price of €131.52 (19.8% above fair value)
  • GF Score™: 83/100 with 6 warning signs

No single metric tells the full story. See the FRA:NOT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novartis AG Business Description

Address Lichtstrasse 35, Basel, CHE, 4056
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score

Get the complete analysis for FRA:NOT

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€131.52
Price
€109.77
GF Value